K2 Principal Fund’s Pfizer PFE Stock Holding History

K2 Principal Fund’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-70,000	Closed	-$2.58M	–	345
2020 Q4	$2.58M	Buy	+70,000	New	+$2.57M	0.23%	127
2017 Q1	–	Sell	-8,432	Closed	-$260K	–	352
2016 Q4	$260K	Sell	8,432 -36,785	-81%	-$1.12M	0.02%	247
2016 Q3	$1.45M	Hold	45,217	–	–	0.16%	137
2016 Q2	$1.51M	Sell	45,217 -25,296	-36%	-$807K	0.2%	101
2016 Q1	$1.98M	Buy	+70,513	New	+$2.01M	0.27%	84

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

K2 Principal Fund's PFE Position: Q3 2017 in Review

K2 Principal Fund sold out of Pfizer (PFE) in Q3 2017, closing a stake of 22,740 shares — an estimated $725K sold.

K2 Principal Fund first reported a position in PFE in Q4 2016 and held it in 2 quarters. The position peaked at $725K in Q2 2017. 2,042 funds tracked by Wall St. Rank hold PFE as of Q3 2017.

K2 Principal Fund reported no remaining Pfizer position as of Q3 2017 after selling out during the quarter.
K2 Principal Fund sold 22,740 Pfizer shares in Q3 2017, an estimated $725K.
K2 Principal Fund first reported a position in Pfizer in Q4 2016 and held it in 2 quarters.
K2 Principal Fund's Pfizer position peaked at $725K in Q2 2017.
2,042 funds tracked by Wall St. Rank held Pfizer as of Q3 2017.

Based on K2 Principal Fund's 13F filing for Q3 2017, filed 9 Nov 2017.